A review of randomized controlled trials using therapeutic apheresis

Transfusion Medicine Reviews

Volumn 16, Issue 3, 2002, Pages 200-229

  Shehata, Nadine ^a,b,c   Kouroukis, Chrisostomos ^a,b,c   Kelton, John G ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBASE; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HUMAN; INFORMATION RETRIEVAL; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; POLYARTERITIS NODOSA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT OUTCOME; VALIDATION PROCESS; CARDIOVASCULAR SURGERY; DEGENERATIVE DISEASE; ENDOCRINE DISEASE; HEMATOLOGIC DISEASE; KIDNEY DISEASE; METHODOLOGY; SKIN DISEASE;

BLOOD COMPONENT REMOVAL; CARDIOVASCULAR SURGICAL PROCEDURES; ENDOCRINE SYSTEM DISEASES; HEMATOLOGIC DISEASES; HUMANS; KIDNEY DISEASES; NEURODEGENERATIVE DISEASES; RANDOMIZED CONTROLLED TRIALS; SKIN DISEASES;

EID: 0036017878     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2002.33433     Document Type: Article

References (165)

1. A method of human plasmapheresis
2. Plasmapheresis in a case of Waldenstrom's Macroglobulinemia
3. Treatment of Waldenstrom's Macroglobulinemia by plasmapheresis
4. Hypotension associated prekallikrein activator (Hageman-factor fragments) in plasma protein fraction
5. Therapeutic plasma exchange
6. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura
7. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura
8. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura
9. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)
10. The measurement of observer agreement for categorical data
11. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
12. Therapeutic plasma exchange: An update from the Canadian Apheresis Group
13. Plasma exchange in neurological diseases
14. Treatment of acute inflammatory polyneuropathy
15. The Guillain-Barre syndrome
16. Toronto General Hospital controlled trial data plasma exchange therapy in Guillain-Barrre Syndrome
17. Plasma exchange in acute Guillain-Barre syndrome
18. Plasma exchange and prednisone in Guillain-Barre syndrome: A controlled randomized trial
19. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy
20. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy
21. Plasmapheresis and acute Guillain-Barre syndrome
22. Appropriate number of plasma exchanges in Guillain-Barre Syndrome
23. Efficiency of plasma exchange in Guillan-Barre syndrome: Role of replacement fluids
24. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome
25. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome
26. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome
27. Motor conduction studies in Guillain-Barre syndrome: Description and prognostic value
28. Plasma exchange in Guillain-Barre syndrome: One-year follow-up
29. IGIV in neurology-evidence and recommendations
30. Effect of plasmapheresis in myasthenia gravis
31. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients
32. Clinical Experience in more than 2000 patients with
33. The utility of therapeutic plasmapheresis for neurological disorders
34. Opinions about plasma exchange and associated treatments in the therapy of myasthenia gravis
35. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis
36. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule
37. Apheresis in neurological disorders
38. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)
39. Management of neurological disorders
40. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
41. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double blind, sham-controlled, cross-over study
42. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
43. Natural history and treatment of multiple sclerosis
44. Multiple Sclerosis
45. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
46. Intensive immunosuppression in progressive multiple sclerosis. A ranphamide, plasma exchange, and ACTH
47. Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs
48. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis
49. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis
50. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
51. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: A randomized single-masked cross-over pilot study
52. Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS)
53. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis
54. Pemiphigus and bullous pemphigoid
55. Treatment of pemphigus vulgaris
56. Bullous pemphigoid. Therapy and management
57. Controlled study of plasma exchange in pemphigus
58. Plasma exchange in bullous pemphigoid
59. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid
60. Mechanisms of immune injury in rheumatoid arthritis: Evidence for the involvement of T-cells and heat-shock protein
61. Biologic agents for treating rheumatoid arthritis. Concepts and progress
62. Total lymphoid irradiation in rheumatoid arthritis. A ten-year follow-up
63. Lymphapheresis in rhematoid arthritis
64. A double blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthrithis
65. Effect of lymphoplasmapheresis on clinical indices and T-cell subsets in rheumatoid arthritis
66. Filtration Leukocytapheresis therapy in rheumatoid arthritis: A randomized double-blind, placebo-controlled trial
67. Plasmapheresis therapy in rheumatoid arthritis
68. A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis
69. Preliminary criteria for the classification of systemic sclerosis
70. Systemic sclerosis (scleroderma) and related disorders: Clinical aspects
71. Treatment of systemic sclerosis with extracorporeal photochemo-therapy
72. Treatment of patients with systemic sclerosis with extracorporeal photochemotherpay (photopheresis)
73. FDA arthritis advisory committee meeting: Analgesics guidelines; topical nsaids; extracorporeal photochemotherapy in scleroderma
74. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: A study in 165 patients
75. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus coricosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis
76. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients
77. Systemic lupus erythematosus
78. Systemic lupus erythematosus: Emerging concepts. Part 1. Renal, Neuropsychiatric, cardiovascular, pulmonary and hematologic disease
79. End-stage renal disease in systemic lupus erythematosus
80. Randomized trial of plasma exchange in mild systemic lupus erythematosus
81. A randomized trial of plasma exchange in severe acute systemic lupus erythematosus
82. Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A pilot study
83. Long-term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis
84. A controlled trial of plasmapheresis in severe lupus nephritis
85. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: Design of the LPSG trial
86. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis
87. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis
88. Thrombocytopenic purpura and the hemolytic uremic syndrome
89. Exchange transfusion in the treatment of thrombotic thrombocytopenic purpura
90. Plasma infusion in the treatment of thrombotic thrombocytopenic purpura
91. Antibodies to baon Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
92. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
93. The treatment of thrombotic thrombocytopenic purpura: Plasma infusion or exchange?
94. The pathophysiology and management of thrombotic thrombocytopenic purpura
95. Neuropathies associated with paraproteinemia
96. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance
97. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy
98. Multiple myeloma and Waldenstrom's macroglobulinemia
99. Multiple myeloma. Review of 869 cases
100. Plasmapheresis in the treatment of acute renal failure in multiple myeloma
101. Improved survival in multiple myeloma with renal failure
102. Treatment of renal failure associated with multiple myeloma
103. Controlled plasma exchange trial in acute renal failure due to multiple myeloma
104. Therapeutic apheresis in renal and metabolic diseases
105. Management of renal disorders
106. Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy
107. Recovery from Goodpasture's syndrome after immunosup-pressive treatment and plasmapheresis
108. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome
109. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-1984
110. Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome
111. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome
112. Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors
113. Goodpasture's syndrome
114. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: A controlled, multi-center study
115. Lymphactapheresis to treat rapidly progressive glomerulonephritis: A randomized comparison with steroid-pulse treatment
116. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies
117. A prospective randomized trial of plasma exchange in idiopathic crescentic glomerulonephritis
118. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomuerlonephritis. A Swedish multi-center study
119. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges
120. Acute rejection of renal allografts: Mechanistic insights and therapeutic options
121. Rejection after kidney transplantation: New concepts, new therapeutic options
122. Plasma exchange in early kidney graft rejection associated with antidonor antibodies
123. Plasma exchange in acute renal transplant rejection
124. A controlled trial evaluating intensive plasma exchange in renal transplant recipients
125. Plasma exchange in acute renal allograft rejection
126. A controlled trial of plasmapheresis in the treatment of renal allograft rejection
127. Bleeding complications associated with cardiopulmonary bypass
128. Hemostatic drugs
129. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding
130. Bleeding after cardiopulmonary bypass
131. Hematologic Problems in the surgical patient: Bleeding and thrombosis
132. Hemostasis changes during cardiopulmonary bypass surgery
133. Intraperative plasmapheresis in cardiac surgery
134. Autologous platelet-rich plasmapheresis: Risk versus benefit in repeat cardiac operations
135. Autologous platelet-rich plasma does not reduce transfusion of homologous blood products in patients undergoing repeat valvular surgery
136. Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass
137. Preoperative plateletpheresis does not reduce blood loss during cardiac surgery
138. Hematological assessment of patients undergoing plasmapheresis during cardiac surgery
139. Effect of intraoperative plasmapheresis on blood loss in cardiac surgery
140. Preoperative plasmapheresis inpatients undergoing cardiac surgery procedures
141. Influence of acute preoperative plasmapheresis on platelet function in cardiac surgery
142. Plateletpheresis before redo CABG diminishes excessive blood transfusion
143. Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery
144. The role of the protein C-thromomodulin system and fibrinolysis during cardiovascular surgery: Influence of acute preoperative plasmapheresis
145. Coagulation tests, blood loss, and transfusion requirements in platelet-rich plasmapheresed versus nonpheresed cardiac surgery patients
146. The haemostatic effectiveness of autologous platelet rich plasma sequesterd after heparin administration and institution of cardiopulmonary bypass
147. Effects of acute intraoperative plasmapheresis in cardiac surgery
148. The influence of acute preoperative plasmapheresis on coagulation test, fibrinolysis, blood loss and transfusion requirements in cardiac surgery
149. Platelet-rich plasma sequestration, with therapeutic platelet yields reduces allogeneic transfusion in complex cardiac surgery
150. Reoperative coronary surgery. Comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass
151. Platelet-rich plasmapheresis in cardiac surgery: A meta-analysis of the effect on transfusion requirements
152. Therapeutic plasma exchange in renal, rheumatic and miscellaneous disorders
153. Prospective randomized cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia
154. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system
155. Familial hypercholesterolemia regression study: A randomized trial of low-density-lipoprotein apheresis
156. Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis
157. Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: A prospective, randomized study
158. Continuous plasmafiltration in sepsis syndrome
159. Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial
160. Treatment of Crohn's disease by lymphocyte apheresis: A randomized controlled trial
161. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis
162. A randomized trial of plasma exchange in the treatment of burn shock
163. Controlled trial of plasma exchange in treatment of Raynaud's syndrome
164. Double-blind evaluation of plasmapheresis in schizophrenic patients: A pilot study
165. Evolution des indications et techniques des echanges plasmatiques. Les enseignements du Registre Francais d'Hemapherese